Antibiotics before infection: a new strategy to protect ICU patients?

NCT ID NCT07203638

ENROLLING_BY_INVITATION Prevention Sponsor: Esraa Salah Mohamed Abdallah Eladl Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving antibiotics early can prevent ventilator-associated pneumonia (VAP) in adults on breathing machines. One hundred participants will receive either the antibiotic cefepime or a placebo for two days. The goal is to see if this approach reduces the number of patients who develop pneumonia during their first week on a ventilator.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Beta lactam antibiotics (cefepime)
What this could lead to: If it works, this could provide a simple way to prevent a common and dangerous lung infection in patients on breathing machines.
What could go wrong: This is a small, early-stage trial. The antibiotics may not prevent pneumonia and could lead to side effects or antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTILATOR-ASSOCIATED PNEUMONIA (VAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTILATOR-ASSOCIATED PNEUMONIA (VAP)

Contacts and locations

Locations

Benha university hospital

Banhā, Al-Qalyubia, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.